Solitary fibrous tumor
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- Solitary fibrous tumor (SFT) represents a diverse group of ubiquitous rare spindle cell neoplasms that may be benign or malignant and that most frequently arises from the pleura and peritoneum and rarely from other sites such as head and neck, liver and skeletal muscle. SFT may be clinically asymptomatic or may present with enlarging mass, compressive effects depending on the site involved and rarely with paraneoplastic manifestations (osteoarthropathy or hypoglycemia).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Solitary fibrous tumor
- Therapeutic area
- Oncology
- solitary fibrous tumor
- SFT
- localised fibrous mesothelioma
- localised fibrous tumour
- localized fibrous mesothelioma
- localized fibrous tumor
- solitary fibrous tumor
- submesothelial fibroma
- solitary fibrous tumor/hemangiopericytoma
- Severity
- Mild
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0016238
- Parent condition
- MONDO:0006209
Related records
Broader conditions (11)
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Fibroblastic neoplasm
- Human disease
- Mesenchymal cell neoplasm
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (11)
- Adult malignant hemangiopericytoma
- Childhood malignant hemangiopericytoma
- Conventional malignant hemangiopericytoma
- Dedifferentiated solitary fibrous tumor
- Hemangiopericytoma, malignant
- Liver solitary fibrous tumor
- Malignant mediastinum hemangiopericytoma
- Malignant peritoneal solitary fibrous tumor
- Malignant pleural solitary fibrous tumor
- Peritoneal solitary fibrous tumor
- Pleural solitary fibrous tumor
Trials (10)
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- Eribulin in Advanced Solitary Fibrous Tumor
- Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
- Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
- Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
- Trial of Dasatinib in Advanced Sarcomas
- Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
- Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Drugs in development (3)
- Axitinib Phase 2
- Eribulin Phase 2
- Pazopanib Phase 2